Capecitabine in the treatment of anal squamous cell carcinoma

Česká verzia

Authors: Lohynská Radka ^1,2; Pechačová Zdeňka ²
Authors place of work: Onkologická klinika 1. LF UK a FTN, Praha ¹; Ústav radiační onkologie 1. LF UK a FN Bulovka, Praha ²
Published in the journal: Klin Onkol 2022; 35(1): 38-43
Category: Reviews
doi: https://doi.org/10.48095/ccko202238

Summary

Background: Anal squamous cell carcinoma (ASCC) is a rare tumor; it accounts for about 2% of gastrointestinal tumors. The goal of the treatment is to preserve the anal sphincter and maintain the quality of life; surgical excision is therefore reserved only for very early stages and in vast majority of cases concomitant chemoradiotherapy (CRT) is indicated, i.e. pelvic irradiation and concomitant mitomycin-based chemotherapy. Technological development in the field of radiodiagnostics, nuclear medicine and radiation therapy has improved the disease staging and enabled more gentle treatment. The standard regimen of chemotherapy has been based on the combination of mitomycin C (MMC) with 5-fluorouracil (5-FU) for many years, with high toxicity. Purpose: The administration of 5-FU + capecitabine regimen provided an opportunity to reduce acute haematological toxicity. A prospective randomized phase II trial EXTRA demonstrated the oncological safety and good toxicity profile of oral capecitabine administered instead of 5-FU. The reduction of severe haematological toxicity and oncological non-inferiority of the capecitabine regimen was also demonstrated by other nine analyses presented in this article. Conclusion: Most international guidelines published by societies such as the National Comprehensive Cancer Network, the European Society for Medical Oncology or the European Society for Therapeutic Radiology and Oncology have accepted capecitabine as a safe alternative to 5-FU in the treatment of ASCC and CRT regimen with oral capecitabine becoming the standard. The advantages are: proven excellent treatment results (non-inferiority towards standard regimens), significant reduction of various types of toxicity and the convenience of outpatient oral capecitabine.

Keywords:

anal cancer – concomitant chemoradiotherapy – mitomycin C – capecitabine – 5-fluorouracil

Zdroje

1. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice. [online]. Dostupné z: https: //www.svod.cz/.

2. Šlampa P, Petera J. Radiační onkologie. Praha: Galén Karolinum 2007: 145–152.

3. Krška Z, Hoskovec D, Petruželka L. Chirurgická onkologie. Praha: Grada 2014: 565–572.

4. Národní radiologické standardy – radiační onkologie. Věstník Ministerstva zdravotnictví České republiky 2/2016. [online]. Dostupné z: https: //www.mzcr.cz/vestnik/vestnik-c-2-2016/.

5. Modrá kniha České onkologické společnosti. [online]. Dostupné z: https: //www.linkos.cz/lekar-a-multidisciplinarni-tym/personalizovana-onkologie/modra-kniha-cos/aktualni-vydani-modre-knihy/.

6. National Comprehensive Cancer Network. Anal Carcinoma (Version 1.2021). [online]. Available from: https: // www.nccn.org/professionals/physician_gls/pdf/anal.pdf.

7. Lohynská R, Nýdlová A, Drbohlavová T et al. Hematologická toxicita u IMRT/VMAT v kurativní léčbě análního karcinomu. Klin Onkol 2020; 33 (4): 288–294. doi: 10.14735/amko2020286.

8. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31 (5): 1341–1346. doi: 10.1016/0360-3016 (95) 00060-C.

9. Glynne-Jones R, Meadows H, Wan S et al. Extra – a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys 2008; 72 (1): 119–126. doi: 10.1016/j.ijrobp.2007.12.012.

10. Deenen MJ, Dewit L, Boot H et al. Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. Int J Radiat Oncol Biol Phys 2013; 85 (5): e201–e207. doi: 10.1016/j.ijrobp.2012.12.008.

11. Meulendijks D, Dewit L, Tomasoa NB et al. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Br J Cancer 2014; 111 (9): 1726–1733. doi: 10.1038/bjc.2014. 467.

12. Thind G, Johal B, Follwell M et al. Chemoradiation with capecitabine and mitomycin-C for stage I–III anal squamous cell carcinoma. Radiat Oncol 2014; 9: 124. doi: 10.1186/1748-717X-9-124.

13. Oliveira SC, Moniz CM, Riechelmann R et al. Phase II study of capecitabine in substitution of 5-FU in the chemoradiotherapy regimen for patients with localized squamous cell carcinoma of the anal canal. J Gastrointest Cancer 2016; 47 (1): 75–81. doi: 10.1007/s12029-015-9 790-4.

14. Peixoto RD, Wan DD, Schellenberg D et al. A comparison between 5-fluorouracil/mitomycin and capecitabine/mitomycin in combination with radiation for anal cancer. J Gastrointest Oncol 2016; 7 (4): 665–672. doi: 10.21037/jgo.2016.06.04.

15. Goodman KA, Julie D, Cercek A et al. Capecitabine with mitomycin reduces acute hematologic toxicity and treatment delays in patients undergoing definitive chemoradiation using intensity modulated radiation therapy for anal cancer. Int J Radiat Oncol Biol Phys 2017; 98 (5): 1087–1095. doi: 10.1016/j.ijrobp.2017.03.022.

16. Jones CM, Adams R, Downing A et al. Toxicity, tolerability, and compliance of concurrent capecitabine or 5-fluorouracil in radical management of anal cancer with single-dose mitomycin-C and intensity modulated radiation therapy: evaluation of a national cohort. Int J Radiat Oncol Biol Phys 2018; 101 (5): 1202–1211. doi: 10.1016/j.ijrobp.2018.04.033.

17. Pumpalova Y, Kozak MM, von Eyben R et al. Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer. J Gastrointest Oncol 2019; 10 (4): 605–615. doi: 10.21037/jgo.2019.02.17.

18. Rotundo MS, Zampino MG, Ravenda PS et al. Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center. Ther Adv Med Oncol 2020; 12: 1758835920940945. doi: 10.1177/1758835920940945.

19. Souza KT, Pereira AA, Araujo RL et al. Replacing 5-fluorouracil by capecitabine in localised squamous cell carcinoma of the anal canal: systematic review and meta-analysis. Ecancermedicalscience 2016; 10: 699. doi: 10.3332/ecancer.2016.699.

20. Benson AB 3rd, Arnoletti JP, Bekaii-Saab T et al. Anal carcinoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012; 10 (4): 449–454. doi: 10.6004/jnccn.212.0046.

21. Glynne-Jones R, Nilsson PJ, Aschele C et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 (Suppl 3): 10–20. doi: 10.1093/annonc/mdu159.

22. Muirhead R, Adams R, Gilbert D. National guidance for IMRT in anal cancer. [online]. Available from: www.analimrtguidance.co.uk.

23. Moureau-Zabotto L, Venderely V, Abromwitz L et al. Anal cancer: French intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP). Dig Liver Dis 2017; 49 (8): 831–840. doi: 10.1016/j.dld.2017.05.011.

24. Eng C, Jácome AA, Das P et al. A phase II study of capecitabine/oxaliplatin with concurrent radiotherapy in locally advanced squamous cell carcinoma of the anal canal. Clin Colorectal Cancer 2019; 18 (4): 301–306. doi: 10.1016/j.clcc.2019.06.003.